Table of Drugs and Targets
Jump to navigation
Jump to search
- Original List of Drugs and Targets
Generic Name | Brand Name | Approval year | Indication | Drug Class | Drug Function |
Cevimeline | Evoxac | 2000 | dry mouth | Cholinergic agonist | M3 muscarinic agonist |
Oxcarbazepine | Trileptal | 2000 | epilepsy | Dibenzazepine | unclear (Na channel inhibitor?) |
Pantoprazole | Protonix | 2000 | gastroesophageal reflux disease | Proton pump inhibitor | gastric acid secretion inhibitor |
Alosetron | Lotronex | 2000 | irritable bowel syndrome | 5-HT3 receptor antagonist | 5-HT3 antagonist |
Pneumococcal 7-valent vaccine | Prevnar | 2000 | Streptococcus pneumoniae | vaccine | vaccine |
moroctocog alpha | ReFacto | 2000 | hemophilia | factor VIII analog | co-factor of thrombin activation cascade |
Zonisamide | Zonegran | 2000 | epilepsy | Sulfonamide anticonvulsant | Sulfonamide anticonvulsant |
Articaine, Epinephrine | Septocaine | 2000 | anesthesia | Local anesthetic | Local anesthesia + vasoconstriction |
Verteporfin | Visudyne | 2000 | macular degeneration | Photosensitizing agent | light-activated phototherapy |
Meloxicam | Mobic | 2000 | osteoarthritis | NSAID | COX-1 and COX-2 inhibitor |
Linezolid | Zyvox | 2000 | Gram-positive infections | Oxazolidinone antibacterial | bacterial protein synthesis inhibitor |
Insulin Glargine | Lantus | 2000 | diabetes | Insulin | Protein replacement therapy |
Rivastigmine | Exelon | 2000 | Alzheimer's disease | Acetylcholinesterase inhibitor | Acetylcholinesterase inhibitor |
Gemtuzumab Ozogamicin | Mylotarg | 2000 | leukemia | conjugated monoclonal antibody | conjugated immunotoxin |
Insulin Aspart | NovoLog | 2000 | diabetes | Insulin | Protein replacement therapy |
Triptorelin | Trelstar Depot | 2000 | prostate cancer | Synthetic gonadotropin-releasing hormone analog | steroid secretion inhibitor |
tenecteplase | TNKase | 2000 | acute myocardial
infarction |
Thrombolytic agent | plasminogen converting enzyme |
Argatroban | Acova | 2000 | thrombosis | Thrombin inhibitor | direct thrombin inhibitor |
Tinzaparin | Innohep | 2000 | deep vein thrombosis | Low molecular weight heparin | antithrombin enhancer |
Balsalazide | Colazal | 2000 | inflammatory bowel disease | 5-Aminosalicylic acid derivative | unclear |
Docosanol | Abreva | 2000 | cold sores, fever blisters from HSV | antiviral | antiviral |
Unoprostone | Rescula | 2000 | glaucoma | Prostaglandin analog | Prostaglandin analog |
Cetrorelix | Cetrotide | 2000 | in-vitro fertilization | GnRH antagonist | GnRH antagonist |
Lopinavir; Ritonavir | Kaletra | 2000 | HIV | Protease inhibitor | HIV protease inhibitor |
Arsenic Trioxide | Trisenox | 2000 | leukemia | DNA fragmentation agent | unclear (DNA fragmentation agent?) |
Mifepristone | Mifeprex | 2000 | contraception | Abortifacient | progesterone receptor antagonist |
crotalidae polyvalent immune Fab, ovine | CroFab | 2000 | Snake Bites | Venom specific immunoglobulin Fab fragment | polyclonal antibody |
Bivalirudin | Angiomax | 2000 | unstable angina | Thrombin inhibitor | direct thrombin inhibitor |
Nateglinide | Starlix | 2000 | diabetes | Meglitinide | insulin secretagogue |
botulinum toxin type B | Myobloc | 2000 | cervical dystonia | neurotoxin | acetylcholine release inhibitor |
Caspofungin | Cancidas | 2001 | aspergillosis | Echinocandin | glucan synthase inhibitor |
Peginterferon alfa-2b | PEGIntron | 2001 | hepatitis C | Pegylated virus proliferation inhibitor | multiple intracellular signal transduction pathways activator |
Ziprasidone | Geodon | 2001 | schizophrenia | Benzisoxazole derivative | D2/5HT2A antagonist |
Formoterol | Foradil | 2001 | asthma | β2-agonist | bronchodilator |
Galantamine | Reminyl | 2001 | Alzheimer's disease | Acetylcholinesterase inhibitor | Acetylcholinesterase inhibitor |
Travoprost | Travatan | 2001 | glaucoma | Prostaglandin analog | PGF2α analog |
Bimatoprost | Lumigan | 2001 | glaucoma | Prostaglandin analog | PGF2α analog |
Almotriptan | Axert | 2001 | migraine | 5-HT1B/1D agonist | 5-HT1B/1D agonist |
Imatinib | Gleevec | 2001 | leukemia | kinase inhibitor | tyrosine kinase inhibitor |
Drospirenone; Ethinyl Estradiol | Yasmin | 2001 | contraception | Estrogen/progestogen combination | ovulation suppression |
alemtuzumab | Campath | 2001 | leukemia | Monoclonal antibody/CD52-blocker | ADCC |
Nesiritide | Natrecor | 2001 | congestive heart failure | Human B-type natriuretic peptide | smooth muscle cell relaxation |
Zoledronic Acid | Zometa | 2001 | hypercalcemia of malignancy | Bisphosphonate | osteoclast inhibitor |
Cefditoren | Spectracef | 2001 | Chronic Bronchitis, Pharyngitis/Tonsillitis, skin infections | Cephalosporin | bacterial cell wall synthesis inhibitor |
darbepoetin alfa | Aranesp | 2001 | anemia | erythropoiesis-stimulating agent | erythropoietin receptor activator |
digoxin immune fab [ovine] | DigiFab | 2001 | digoxin toxicity | Immune Globulin | digoxin sequestration |
Etonogestrel; Ethinyl Estradiol Vaginal Ring | NuvaRing | 2001 | contraception | Estrogen/progestogen combination | ovulation suppression |
Tenofovir | Viread | 2001 | HIV | Nucleotide analogue reverse transcriptase inhibitor | HIV-1 reverse transcriptase inhibitr |
Frovatriptan | Frova | 2001 | migraine | 5-HT1B/1D agonist | 5-HT1B/1D agonist |
Valdecoxib | Bextra | 2001 | inflammation, pain, dysmenorrhea | NSAID | COX-2 inhibitor |
Bosentan | Tracleer | 2001 | pulmonary arterial hypertension | Endothelin antagonist | vasodilatation |
Dutasteride | Avodart | 2001 | prostatic hyperplasia | Type I and II 5 α-reductase inhibitor | testosterone conversion enzyme inhibitor |
Norelgestromin; Ethinyl Estradiol | Ortho Evra | 2001 | contraception | Estrogen/progestogen combination | ovulation suppression |
Ertapenem | Invanz | 2001 | gram+ and gram- infections | Carbapenem | bacterial cell wall synthesis inhibitor |
anakinra | Kineret | 2001 | rheumatoid arthritis | Interleukin-1 antagonist | IL-1 inhibitor |
drotrecogin alfa | Xigris | 2001 | sepsis | blood coagulation cascade inhibitor | factors Va/VIIIa inhibitor |
Fondaparinux | Arixtra | 2001 | deep vein thrombosis | Specific factor Xa inhibitor | antithrombin III potentiator |
Pimecrolimus | Elidel | 2001 | atopic dermatitis | Macrolactam ascomycin derivative | unclear (IL-2 inhibitor?) |
Desloratadine | Clarinex | 2001 | allergic rhinitis | H1-antagonist | histamine release inhibitor |
Nitisinone | Orfadin | 2002 | hereditary tyrosinemia type 1 | 4-hydroxyphenylpyruvate dioxygenase inhibitor | 4-hydroxyphenylpyruvate dioxygenase inhibitor |
pegfilgrastim | Neulasta | 2002 | neutropenia | Granulocyte colony stimulating factor | hematopoiesis stimulator |
ibritumomab tiuxetan | Zevalin | 2002 | lymphoma | Monoclonal antibody/CD20-blocker | conjugated radioimmunotherapy |
interferon beta 1a | Rebif | 2002 | multiple sclerosis | Biological response modifier | unclear ((IFNAR1/IFNAR2c modulator) |
Fulvestrant | Faslodex | 2002 | breast cancer | Estrogen receptor antagonist | Estrogen receptor antagonist |
Olmesartan | Benicar | 2002 | hypertension | Angiotensin II receptor antagonist | angiotensin II receptor antagonist |
Treprostinil | Remodulin | 2002 | pulmonary arterial hypertension | Pulmonary and systemic vasodilator | vasodilatation |
Voriconazole | Vfend | 2002 | Aspergillus and Candida infections | Azole antifungal | ergosterol synthesis inhibitor |
Sodium Oxybate | Xyrem | 2002 | Cataplexy | CNS Depressant | unclear (GHB/GABA(B) modulator?) |
Tegaserod | Zelnorm | 2002 | irritable bowel syndrome | 5-HT4 agonist | 5-HT4 agonist |
rasburicase | Elitek | 2002 | tumor lysis syndrome | enzyme | uric acid conversion enhancer |
Oxaliplatin | Eloxatin | 2002 | colorectal cancer | Organoplatinum complex | DNA synthesis inhibitor |
Adefovir | Hepsera | 2002 | hepatitis B | Nucleotide analogue reverse transcriptase inhibitor | HBV DNA polymerase inhibitor |
Eplerenone | Inspra | 2002 | chronic heart failure | Aldosterone blocker | Aldosterone blocker |
Ezetimibe | Zetia | 2002 | hypercholesterolemia | Cholesterol absorption inhibitor | Cholesterol absorption inhibitor |
peginterferon alfa-2a | Pegasys | 2002 | hepatitis C | Pegylated virus proliferation inhibitor | unclear ((IFNAR1/IFNAR2c modulator) |
Aripiprazole | Abilify | 2002 | schizophrenia | Partial D2/5HT1A agonist/5HT2A antagonist | Partial D2/5HT1A agonist and 5HT2A antagonist |
Nitazoxanide | Alinia | 2002 | giardia, cryptosporidium infections | Antiprotozoal agent | disruption of anaerobic energy metabolism |
Atomoxetine | Strattera | 2002 | ADHD | Selective norepinephrine reuptake inhibitor | Selective norepinephrine reuptake inhibitor |
Teriparatide | Forteo | 2002 | osteoporosis | Recombinant human parathyroid hormone | Protein replacement therapy |
Icodextrin | Extraneal | 2002 | chronic renal failure | sequestering agent | sequestering agent |
alpha-1-antitrypsin | Aralast | 2002 | Alpha 1-antitrypsin deficiency | α1-Proteinase Inhibitor | Enzyme replacement therapy |
Eletriptan | Relpax | 2002 | migraine | 5-HT1B/1D agonist | 5-HT1B/1D agonist |
adalimumab | Humira | 2002 | rheumatoid arthritis | Monoclonal antibody/TNFα blocker | TNFα blocker |
alefacept | Amevive | 2003 | psoriasis | Immunosuppressive agent | Immunosuppressive agent |
Enfuvirtide | Fuzeon | 2003 | HIV | Fusion inhibitor | entry inhibitor |
Pegvisomant | Somavert | 2003 | acromegaly | GH receptor antagonist | disruption of GH signal transduction |
Aprepitant | Emend | 2003 | emesis | neurokinin-1 antagonist | neurokinin-1 antagonist |
Gemifloxacin | Factive | 2003 | bronchitis, pneumonia | Fluoroquinolone | DNA synthesis inhibitor |
agalsidase beta | Fabrazyme | 2003 | Fabry's disease | enzyme | Enzyme replacement therapy |
Laronidase | Aldurazyme | 2003 | Mucopolysaccharidosis | enzyme | Enzyme replacement therapy |
Gefitinib | Iressa | 2003 | lung cancer | Kinase inhibitor | tyrosine kinase inhibitor |
Bortezomib | Velcade | 2003 | multiple myeloma | Proteasome inhibitor | proteasome inhibitor |
Ibandronic acid | Boniva | 2003 | osteoporosis | Bisphosphonate | osteoclast inhibitor |
Alfuzosin | Uroxatral | 2003 | prostatic hyperplasia | α1-antagonist | α1-antagonist |
Atazanavir | Reyataz | 2003 | HIV | Protease inhibitor | HIV protease inhibitor |
tositumomab and tositumomab I-131 | Bexxar | 2003 | lymphoma | Monoclonal antibody/CD20-blocker | conjugated radioimmunotherapy |
omalizumab | Xolair | 2003 | asthma | Monoclonal antibody/IgE-blocker | IgE receptor blocker |
Emtricitabine | Emtriva | 2003 | HIV | Nucleoside reverse transcriptase inhibitor | HIV DNA polymerase inhibitor |
Alpha-1-Proteinase Inhibitor (Human) | Zemaira | 2003 | Alpha 1-antitrypsin deficiency | α1-Proteinase Inhibitor | Enzyme Replacement therapy |
Palonosetron | Aloxi | 2003 | emesis | 5-HT3 receptor antagonist | 5-HT3 antagonist |
Recombinant clotting factor VIII | Advate | 2003 | hemophilia | factor VIII analog | co-factor of thrombin activation cascade |
Miglustat | Zavesca | 2003 | Gaucher's disease | enzyme inhibitor | Substrate reduction therapy |
Rosuvastatin | Crestor | 2003 | hypercholesterolemia | HMG-CoA reductase inhibitor | HMG-CoA reductase inhibitor |
Vardenafil | Levitra | 2003 | erectile dysfunction | PDE5 inhibitor | PDE5 inhibitor |
Immune Globulin Intravenous (Human), 10% by Chromatography Process | Gamunex | 2003 | idiopathic thrombocytopenic purpura, primary immune deficiency | Immune Globulin | unclear |
Daptomycin | Cubicin | 2003 | Gram-positive infections | Cyclic lipopeptide | bacterial DNA, RNA and protein synthesis inhibitor |
Prussian Blue | Radiogardase | 2003 | caesium-137 poisoning | sequestering agent | sequestering agent |
Epinastine | Elestat | 2003 | allergic conjunctivitis | H1-antagonist | histamine release inhibitor |
Memantine | Namenda | 2003 | Alzheimer's disease | NMDA receptor antagonist | NMDA receptor antagonist |
Botulism Immune Globulin | BabyBIG | 2003 | infant botulism | Immune Globulin | unclear |
efalizumab | Raptiva | 2003 | psoriasis | Monoclonal antibody/anti-CD11a | lymphocyte activation inhibitor |
Tadalafil | Cialis | 2003 | erectile dysfunction | PDE5 inhibitor | PDE5 inhibitor |
Abarelix | Plenaxis | 2003 | prostate cancer | GnRH antagonist | GnRH antagonist |
Sertaconazole | Ertaczo | 2003 | interdigital tinea pedis | Azole antifungal | ergosterol synthesis inhibitor |
Immune Globulin Intravenous (Human) | Flebogamma | 2003 | primary immune deficiency | Immune Globulin | unclear |
Tiotropium | Spiriva | 2004 | COPD | Muscarinic antagonist | M3 muscarinic acetylcholine antagonist |
Pemetrexed | Alimta | 2004 | mesothelioma | Antifolate | purine and pyrimidine synthesis inhibitor |
Cetuximab | Erbitux | 2004 | colorectal cancer | Monoclonal antibody/EGFR-blocker | EGFR inhibitor |
Bevacizumab | Avastin | 2004 | colorectal cancer | Monoclonal antibody/VEGF blocker | angiogenesis inhibitor |
Cinacalcet | Sensipar | 2004 | hyperparathyroidism, hypercalcemia | Calcimimetic agent | calcium-sensing receptor activator |
Telithromycin | Ketek | 2004 | bronchitis, sinusitis, pneumonia | Ketolide antibiotic | bacterial protein synthesis inhibitor |
Insulin Glulisine | Apidra | 2004 | diabetes | Insulin | Protein replacement therapy |
Apomorphine | Apokyn | 2004 | Parkinson's disease | Non-ergoline dopamine agonist | Non-ergoline dopamine agonist |
Tinidazole | Tindamax | 2004 | Trichomoniasis, giardiasis, amebiasis | Antiprotozoal agent | unclear |
Azacitidine | Vidaza | 2004 | myelodysplastic syndrome | DNA methyltransferase inhibitor | apoptosis |
Immune Globulin Intravenous (Human) | Octagam | 2004 | primary immune deficiency | Immune Globulin | unclear |
Rifaximin | Xifaxan | 2004 | travelers’ diarrhea | Semisynthetic rifampin analog | bacterial RNA synthesis inhibitor |
Trospium | Sanctura | 2004 | Overactive bladder | Muscarinic antagonist | M1 Muscarinic acetylcholine antagonist |
L-Glutamine | NutreStore | 2004 | Short
Bowel Syndrome |
Dietary supplement | unclear |
Acamprosate | Campral | 2004 | alcohol dependence | GABA analog | GABA analog |
Duloxetine | Cymbalta | 2004 | depression | Serotonin and norepinephrine reuptake inhibitor | Serotonin and norepinephrine reuptake inhibitor |
Lanthanum | Fosrenol | 2004 | end stage renal disease | Phosphate binder | phosphate sequestration |
Omega-3 acids | Lovaza | 2004 | hypertriglyceridemia | Lipid-regulating agent | unclear |
Erlotinib | Tarceva | 2004 | pancreatic cancer | kinase inhibitor | tyrosine kinase inhibitor |
Solifenacin | VESIcare | 2004 | Overactive bladder | Muscarinic antagonist | M3 muscarinic acetylcholine antagonist |
natalizumab | Tysabri | 2004 | multiple sclerosis | Monoclonal antibody/VCAM-1 blocker | α4 integrin antagonist |
Palifermin | Kepivance | 2004 | oral mucositis | Keratinocyte growth factor | epithelial cell proliferation |
Eszopiclone | Lunesta | 2004 | insomnia | Nonbenzodiazepine hypnotic agent | unclear (GABA-A agonist?) |
Pegaptanib | Macugen | 2004 | age-related macular degeneration | VEGF inhibitor | VEGF antagonist |
Darifenacin | Enablex | 2004 | Overactive bladder | Muscarinic antagonist | M3 muscarinic acetylcholine antagonist |
Ziconotide | Prialt | 2004 | pain | N-type Calcium Channel Blocker | N-type Calcium Channel Blocker |
Clofarabine | Clolar | 2004 | leukemia | Antimetabolite | DNA synthesis inhibitor |
Iloprost | Ventavis | 2004 | pulmonary arterial hypertension | Prostaglandin analog | vasodilatation |
Pregabalin | Lyrica | 2004 | pain associated with diabetic peripheral neuropathy | GABA analog | GABA analog |
Pramlintide | Symlin | 2005 | diabetes | Synthetic amylin analog | Protein replacement therapy |
Micafungin | Mycamine | 2005 | Candida infections | Echinocandin | glucan synthase inhibitor |
Entecavir | Baraclude | 2005 | hepatitis B | Nucleoside reverse transcriptase inhibitor | HBV DNA polymerase inhibitor |
Immune Globulin Intravenous [Human] Solution | Gammagard | 2005 | primary immune deficiency | Immune Globulin | unclear |
Exenatide | Byetta | 2005 | diabetes | Incretin mimetic | GLP-1 agonist |
CNJ-016, Vaccinia Immune Globulin Intravenous (Human) | VIGIV | 2005 | complications of vaccinia vaccination | vaccine | vaccine |
Galsulfase | Naglazyme | 2005 | Mucopolysaccharidosis VI | Enzyme | Enzyme replacement therapy |
Tigecycline | Tygacil | 2005 | broad-spectrum infections | Glycylcycline | bacterial protein synthesis inhibitor |
Insulin Detemir | Levemir | 2005 | diabetes | insulin | Protein replacement therapy |
Tipranavir | Aptivus | 2005 | HIV | Protease inhibitor | HIV protease inhibitor |
Ramelteon | Rozerem | 2005 | insomnia | Melatonin agonist | MT1 and MT2 receptor agonist |
Nepafenac | Nevanac | 2005 | pain, inflammation | NSAID | prostaglandin biosynthesis inhibitor |
Mecasermin Recombinant | Increlex | 2005 | growth failure in children with severe primary IGF-1 deficiency | IGF-1 | IGF-1 receptor activator |
Nelarabine | Arranon | 2005 | leukemia | Deoxyguanosine analogue | DNA synthesis inhibitor |
Deferasirox | Exjade | 2005 | hemochromatosis | Iron-chelating agent | iron sequestration |
Mecasermin Rinfabate [rDNA Origin] | Iplex | 2005 | growth failure in children with severe primary IGF-1 deficiency | IGF-1/IGFBP-3 complex | IGF-1 receptor activator |
Sorafenib | Nexavar | 2005 | renal cell carcinoma | Kinase inhibitor | tyrosine kinase inhibitor |
Abatacept | Orencia | 2005 | rheumatoid arthritis | Selective costimulation modulator | CTLA4-Ig agonist |
Lenalidomide | Revlimid | 2005 | multiple myeloma | Thalidomide Analog | apoptosis, anti-angiogenesis, anti-osteoclastogenesis |
Conivaptan | Vaprisol | 2005 | Hyponatremia | Arginine vasopressin antagonist | V1A/V2 receptor antagonist |
Immune Globulin Subcutaneous (Human) | Vivaglobin | 2006 | primary immune deficiency | Immune Globulin | unclear |
Sunitinib | Sutent | 2006 | renal cell carcinoma, GIST | Kinase inhibitor | tyrosine kinase inhibitor |
Ranolazine | Ranexa | 2006 | angina pectoris | partial fatty acid oxidation inhibitors | unclear (pFOX inhibitor?) |
Hepatitis B Immune Globulin (Human) | HepaGam B | 2006 | hepatitis B | Immune Globulin | unclear |
lubiprostone | Amitiza | 2006 | irritable bowel syndrome | Chloride channel activator | ClC-2 chloride channel activator |
Rotavirus Vaccine, Live, Oral, Pentavalent | RotaTeq | 2006 | rotavirus | vaccine | vaccine |
Anidulafungin | Eraxis | 2006 | Candida infections | Echinocandin | glucan synthase inhibitor |
Alglucosidase alfa | Myozyme | 2006 | Pompe disease | enzyme | Enzyme replacement therapy |
decitabine | Dacogen | 2006 | myelodysplastic syndrome | DNA methyltransferase inhibitor | apoptosis |
varenicline | Chantix | 2006 | smoking addiction | Nicotinic Acetylcholine Agonist | α4β2 neuronal nicotinic acetylcholine receptor agonist |
rasagiline | Azilect | 2006 | Parkinson's disease | Monoamine oxidase inhibitor (Type B) | MAO-B inhibitor |
Zoster Vaccine, Live | Zostavax | 2006 | shingles | vaccine | vaccine |
Human papillomavirus vaccine | Gardasil | 2006 | cervical cancer | vaccine | vaccine |
darunavir | Prezista | 2006 | HIV | Protease inhibitor | HIV protease inhibitor |
dasatinib | Sprycel | 2006 | leukemia | Kinase inhibitor | tyrosine kinase inhibitor |
ranibizumab | Lucentis | 2006 | macular degeneration | Monoclonal antibody/VEGF-A blocker | angiogenesis inhibitor |
idursulfase | Elaprase | 2006 | Hunter syndrome | Enzyme | Enzyme replacement therapy |
posaconazole | Noxafil | 2006 | Aspergillus and Candida infections | Azole antifungal | ergosterol synthesis inhibitor |
panitumumab | Vectibix | 2006 | colorectal cancer | Monoclonal antibody/EGFR-blocker | EGFR inhibitor |
biskalcitrate; metronidazole; tetracycline hydrochloride | Pylera | 2006 | Helicobacter pylori | antimicrobial combination against H. Pylori | unclear |
vorinostat | Zolinza | 2006 | lymphoma | Histone deacetylase inhibitor | histone deacetylase inhibitor |
sitagliptin | Januvia | 2006 | diabetes | Dipeptidyl peptidase-4 inhibitor | DPP4 inhibitor |
ciclesonide | Omnaris | 2006 | allergic rhinitis | Non-halogenated glucocorticoid | unclear |
telbivudine | Tyzeka | 2006 | hepatitis B | Nucleoside reverse transcriptase inhibitor | HBV DNA polymerase inhibitor |
Sinecatechins | Veregen | 2006 | external genital and perianal warts | Sinecatechins | unclear |
paliperidone | Invega | 2006 | schizophrenia | Benzisoxazole derivative | D2/5HT2A antagonist |
lisdexamfetamine | Vyvanse | 2007 | ADHD | Sympathomimetic amine | Norepinephrine-dopamine reuptake inhibitor |
aliskiren | Tekturna | 2007 | hypertension | Renin inhibitor | renin inhibitor |
lapatinib | Tykerb | 2007 | breast cancer | Kinase inhibitor | tyrosine kinase inhibitor |
eculizumab | Soliris | 2007 | paroxysmal nocturnal hemoglobinuria | Monoclonal antibody/Protein C5 blocker | Complement C5 inhibitor |
Protein C Concentrate (Human) | Ceprotin | 2007 | venous thrombosis, purpura fulminans | Vitamin K-dependent coagulation factor inhibitor | factors Va/VIIIa inhibitor |
retapamulin | Altabax | 2007 | bacterial skin infections | Pleuromutilin antibacterial | bacterial protein synthesis inhibitor |
rotigotine | Neupro | 2007 | Parkinson's disease | Non-ergoline dopamine agonist | Non-ergoline dopamine agonist |
temsirolimus | Torisel | 2007 | renal cell carcinoma | mTOR inhibitor | mTOR inhibitor |
ambrisentan | Letairis | 2007 | pulmonary arterial hypertension | Endothelin antagonist | vasodilatation |
Immune Globulin Intravenous (Human), 10% Liquid | Privigen | 2007 | Primary immunodeficiency, Chronic immune thrombocytopenic purpura | Immune Globulin | unclear |
Maraviroc | Selzentry | 2007 | HIV | CCR5 co-receptor antagonist | entry inhibitor |
Thrombin, Topical (Human) | Evithrom | 2007 | hemostasis | Topical Thrombin | fibrinogen activator |
Lanreotide | Somatuline Depot | 2007 | acromegaly | Somatostatin analog | GH inhibitor |
doripenem | Doribax | 2007 | Complicated intra-abdominal infections, Complicated urinary tract infections, including pyelonephritis | Carbapenem | bacterial cell wall synthesis inhibitor |
raltegravir | Isentress | 2007 | HIV | HIV-integrase strand transfer inhibitor | HIV-1 integrase inhibitor |
ixabepilone | Ixempra | 2007 | breast cancer | Antimicrotubule agent | mitotic inhibitor |
nilotinib | Tasigna | 2007 | leukemia | Kinase inhibitor | tyrosine kinase inhibitor |
methoxy polyethylene glycol-epoetin beta | Mircera | 2007 | anemia | erythropoiesis-stimulating agent | erythropoietin receptor activator |
sapropterin | Kuvan | 2007 | Phenylketonuria | Synthetic tetrahydrobiopterin | phenylalanine hydroxylase activator |
nebivolol | Bystolic | 2007 | hypertension | Selective β1-blocker | Selective β1-blocker |
Etravirine | Intelence | 2008 | HIV | Non-nucleoside reverse transcriptase inhibitor | Non-nucleoside reverse-transcriptase inhibitor |
Rilonacept | Arcalyst | 2008 | cryopyrin-associated periodic syndromes | Interleukin-1 antagonist | IL-1 inhibitor |
Desvenlafaxine | Pristiq | 2008 | depression | Serotonin and norepinephrine reuptake inhibitor | Serotonin and norepinephrine reuptake inhibitor |
Bendamustine | Treanda | 2008 | leukemia | Alkylating agent | Alkylating agent |
Rotavirus vaccine | Rotarix | 2008 | rotavirus | vaccine | vaccine |
Certolizumab pegol | Cimzia | 2008 | Crohn’s disease | Monoclonal antibody/TNFα blocker | TNFα blocker |
Methylnaltrexone | Relistor | 2008 | constipation | Opioid antagonist | µ-opioid antagonist |
Alvimopan | Entereg | 2008 | recovery from surgery | Opioid antagonist | µ-opioid antagonist |
Peginterferon + Ribavirin | Pegpak | 2008 | Hepatitis C | antiviral | antiviral |
Difluprednate | Durezol | 2008 | occular inflammation, pain | Corticosteroid | Corticosteroid |
Clevidipine | Cleviprex | 2008 | hypertension | L-type Calcium channel blocker (dihydropyridine) | Calcium channel blocker (dihydropyridine) |
Tetrabenazine | Xenazine | 2008 | Huntington's Disease | Monoamine depletor | VMAT-inhibitor |
Romiplostim | Nplate | 2008 | Idiopathic thrombocytopenic purpura | Thrombopoietin receptor agonist | Thrombopoietin receptor agonist |
Silodosin | Rapaflo | 2008 | benign prostatic hyperplasia | α1-antagonist | α1-antagonist |
C1 Esterase Inhibitor (Human) | Cinryze | 2008 | Hereditary angioedema | C1 inhibitor | C1 esterase inhibitor |
Lacosamide | Vimpat | 2008 | epilepsy | Sodium channel inactivator | unclear (Na channel inhibitor?) |
Fesoterodine | Toviaz | 2008 | Overactive bladder | Muscarinic antagonist | Muscarinic antagonist (multiple subtypes) |
Rufinamide | Banzel | 2008 | Lennox-Gastaut syndrome | Triazole derivative | unclear |
Eltrombopag | Promacta | 2008 | Thrombocytopenia | Thrombopoietin receptor agonist | Thrombopoietin receptor agonist |
Tapentadol | Nucynta | 2008 | pain | Analgesic | µ-opioid agonist; norepinephrine reuptake inhibitor |
Fospropofol | Lusedra | 2008 | general anesthesia | Anesthetic agent | GABA-A agonist |
Plerixafor | Mozobil | 2008 | lymphoma, myeloma | Hematopoetic stem cell mobilizer | CXCR4 chemokine inhibitor |
Degarelix | Firmagon | 2008 | prostate cancer | GnRH antagonist | GnRH antagonist |
Milnacipran | Savella | 2009 | Fibromyalgia | Serotonin and norepinephrine reuptake inhibitor | Serotonin and norepinephrine reuptake inhibitor |
Febuxostat | Uloric | 2009 | hyperuricemia | Xanthine oxidase inhibitor | Xanthine oxidase inhibitor |
Everolimus | Afinitor | 2009 | pancreatic cancer, renal cell carcinoma, Astrocytoma | Kinase inhibitor | mTOR inhibitor |
Artemether + Lumefantrine | Coartem | 2009 | malaria | Artemisinin-based combination therapy | Artemisinin-based combination therapy |
Golimumab | Simponi | 2009 | Rheumatoid arthritis, Psoriatic Arthritis, Ankylosing spondylitis | Monoclonal antibody/TNFα blocker | TNFα blocker |
AbobotulinumtoxinA | Dysport | 2009 | cervical dystonia | neurotoxin | acetylcholine release inhibitor |
Iloperidone | Fanapt | 2009 | schizophrenia | Benzisoxazole derivative | D2/5HT2A antagonist |
Tolvaptan | Samsca | 2009 | Hyponatremia | Arginine vasopressin antagonist | V2 receptor antagonist |
Besifloxacin | Besivance | 2009 | bacterial conjunctivitis | Fluoroquinolone | DNA synthesis inhibitor |
Canakinumab | Ilaris | 2009 | Muckle–Wells syndrome, familial cold autoinflammatory syndrome, neonatal-onset multisystem inflammatory disease | Monoclonal antibody/IL-1β | IL-1β inhibitor |
Dronedarone | Multaq | 2009 | cardiac arrhythmia | Class III antiarrhythmic | Class III antiarrhythmic |
Prasugrel | Effient | 2009 | thrombosis | Platelet aggregation inhibitor | Platelet aggregation inhibitor |
Saxagliptin | Onglyza | 2009 | diabetes | Dipeptidyl peptidase-4 inhibitor | DPP4 inhibitor |
Pitavastatin | Livalo | 2009 | hypercholesterolemia | HMG-CoA reductase inhibitor | HMG-CoA reductase inhibitor |
Asenapine | Saphris | 2009 | schizophrenia | Dibenzazepine | D2/5HT2A antagonist |
Vigabatrin | Sabril | 2009 | epilepsy | GABA analog | GABA analog |
Bepotastine | Bepreve | 2009 | allergic conjunctivitis | H1-antagonist | histamine release inhibitor |
Telavancin | Vibativ | 2009 | skin infections | Lipoglycopeptide antibacterial agent | bacterial cell wall synthesis inhibitor |
Pralatrexate | Folotyn | 2009 | lymphoma | Dihydrofolic acid reductase inhibitor | Folate analog metabolic inhibitor |
Ustekinumab | Stelara | 2009 | psoriasis | Monoclonal antibody/IL-12 and IL-23 blocker | IL-12 and IL-23 inhibitor |
C1 Esterase Inhibitor (Human) | Berinert | 2009 | Hereditary angioedema | C1 inhibitor | C1 esterase inhibitor |
Human papilloma virus vaccine | Cervarix | 2009 | cervical cancer | Vaccine | Vaccine |
Alpha1-Proteinase Inhibitor | Prolastin-C | 2009 | panacinar emphysema | α1-Proteinase Inhibitor | Enzyme Replacement therapy |
Pazopanib | Votrient | 2009 | renal cell carcinoma | Kinase inhibitor | tyrosine kinase inhibitor |
Ofatumumab | Arzerra | 2009 | leukemia | Monoclonal antibody/CD20-blocker | B lymphocyte inhibition |
Romidepsin | Istodax | 2009 | lymphoma | Histone deacetylase inhibitor | Histone deacetylase inhibitor |
Capsaicin | Qutenza | 2009 | Postherpetic neuralgia | Analgesic | TRPV1 channel agonist |
Ecallantide | Kalbitor | 2009 | hereditary angioedema | Plasma kallikrein inhibitor | Plasma kallikrein inhibitor |
Tocilizumab | Actemra | 2010 | Rheumatoid arthritis | Monoclonal antibody/IL-6-blocker | IL-6 antagonist |
Dalfampridine | Ampyra | 2010 | multiple sclerosis | Potassium channel blocker | Potassium channel blocker |
Liraglutide | Victoza | 2010 | diabetes | Incretin mimetic | GLP-1 agonist |
Collagenase clostridium histolyticum | Xiaflex | 2010 | Dupuytren's contracture | Debriding/Healing Agent | anti-collagen enzyme |
Velaglucerase alfa | Vpriv | 2010 | Gaucher's disease | enzyme | Enzyme replacement therapy |
Immune Globulin (Human) | Hizentra | 2010 | primary immune deficiency | Immune Globulin | unclear |
Carglumic Acid | Carbaglu | 2010 | Hyperammonemia | Carbamoyl Phosphate Synthetase 1 | enzyme activator |
Polidocanol | Asclera | 2010 | varicose veins | Sclerosing Agent | Sclerosing Agent |
Sipuleucel-T | Provenge | 2010 | prostate cancer | Immunomodulator | immunostimulant |
Estradiol valerate + dienogest | Natazia | 2010 | contraception | Estrogen/progestogen combination | ovulation suppression |
Alglucosidase alfa | Lumizyme | 2010 | Pompe disease | enzyme | Enzyme replacement therapy |
Denosumab | Prolia | 2010 | osteoporosis | Monoclonal antibody/RANKL-blocker | osteoclast inhibitor |
Cabazitaxel | Jevtana | 2010 | prostate cancer | Antimicrotubule agent | mitotic inhibitor |
Alpha1-Proteinase Inhibitor (Human) | Glassia | 2010 | emphysema | enzyme | Enzyme replacement therapy |
Alcaftadine | Lastacaft | 2010 | allergic conjunctivitis | H1-antagonist | histamine release inhibitor |
incobotulinumtoxinA | Xeomin | 2010 | cervical dystonia, Blepharospasm | neurotoxin | acetylcholine release inhibitor |
Ulipristal | Ella | 2010 | contraception | Emergency contraceptive | selective progesterone receptor modulator |
Pegloticase | Krystexxa | 2010 | gout | Recombinant urate-oxidase enzyme | uric acid conversion enhancer |
Fingolimod | Gilenya | 2010 | multiple sclerosis | Sphingosine 1-phosphate receptor modulator | Sphingosine 1-phosphate modulator |
Dabigatran | Pradaxa | 2010 | stroke | Thrombin inhibitor | direct thrombin inhibitor |
Lurasidone | Latuda | 2010 | schizophrenia | Benzoisothiazol derivative | D2/5HT2A antagonist |
Ceftaroline | Teflaro | 2010 | broad-spectrum infections | Cephalosporin | bacterial cell wall synthesis inhibitor |
Tesamorelin | Egrifta | 2010 | lipodystrophy | Growth hormone-releasing factor | growth hormone release-stimulating peptide |
Eribulin | Halaven | 2010 | breast cancer | Antimicrotubule agent | mitotic inhibitor |
Spinosad | Natroba | 2011 | head lice | Pediculocide | nicotinic acetylcholine receptor activator |
Vilazodone | Viibryd | 2011 | depression | SSRI | 5-HT1A partial agonist |
Factor XIII | Corifact | 2011 | Factor XIII deficiency | Plasma glycoprotein | fibrin cross-linker |
Azilsartan | Edarbi | 2011 | hypertension | Angiotensin II receptor antagonist | angiotensin II receptor antagonist |
Roflumilast | Daliresp | 2011 | COPD | PDE4 inhibitor | PDE4 inhibitor |
Belimumab | Benlysta | 2011 | lupus | Monoclonal antibody/BLyS blocker | BLyS blocker |
Ipilimumab | Yervoy | 2011 | melanoma | Monoclonal antibody/CTLA-4 blocker | T-cell activation through CTLA-4 blockade |
Vandetanib | Caprelsa | 2011 | thyroid cancer | Kinase inhibitor | tyrosine kinase inhibitor |
Gabapentin enacarbil | Horizant | 2011 | Restless Legs Syndrome | GABA analog | GABA analog |
Abiraterone | Zytiga | 2011 | prostate cancer | Nonsteroidal antiandrogen | CYP17A1 inhibitor |
Linagliptin | Tradjenta | 2011 | diabetes | Dipeptidyl peptidase-4 inhibitor | DPP4 inhibitor |
Boceprevir | Victrelis | 2011 | hepatitis C | Protease inhibitor | NS3/4A protease inhibitor |
Rilpivirine | Edurant | 2011 | HIV | Non-nucleoside reverse transcriptase inhibitor | Non-nucleoside reverse-transcriptase inhibitor |
Telaprevir | Incivek | 2011 | hepatitis C | Protease inhibitor | NS3/4A protease inhibitor |
Fidaxomicin | Dificid | 2011 | C. difficile | Macrolide | RNA polymerase inhibitor |
Ezogabine | Potiga | 2011 | epilepsy | Potassium channel opener | Potassium channel opener |
Belatacept | Nulojix | 2011 | Graft Rejection | Selective costimulation modulator | CTLA4-Ig agonist |
Azficel-T | LaViv | 2011 | Smoothing nasolabial fold wrinkles in adults | Autologous dermal fibroblasts | unclear |
Indacaterol | Arcapta | 2011 | COPD | β2-agonist | bronchodilator |
Rivaroxaban | Xarelto | 2011 | deep vein thrombosis | Specific factor Xa inhibitor | Specific factor Xa inhibitor |
Ticagrelor | Brilinta | 2011 | acute coronary syndrome (prevention of thrombotic events) | Platelet aggregation inhibitor | P2Y12 platelet inhibitor |
Vemurafenib | Zelboraf | 2011 | melanoma | Kinase inhibitor | tyrosine kinase inhibitor |
Centruroides (Scorpion) Immune F(ab')2 (Equine) Injection | Anascorp | 2011 | scorpion envenomation | antivenom | immunoglobulin G |
Brentuximab Vedotin | Adcetris | 2011 | lymphoma | conjugated monoclonal antibody | conjugated immunotoxin |
Icatibant | Firazyr | 2011 | hereditary angioedema | Bradykinin B2 antagonist | Bradykinin B2 antagonist |
Crizotinib | Xalkori | 2011 | lung cancer | Kinase inhibitor | tyrosine kinase inhibitor |
Deferiprone | Ferriprox | 2011 | thalassemia | Iron-chelating agent | iron sequestration |
Clobazam | Onfi | 2011 | Lennox-Gastaut syndrome | Benzodiazepine | GABA-A agonist |
Ruxolitinib | Jakafi | 2011 | Myelofibrosis | Kinase inhibitor | Janus kinase inhibitor |
Asparaginase Erwinia chrysanthemi | Erwinaze | 2011 | acute lymphoblastic leukemia | enzyme | asparagine converting enzyme |
Aflibercept | Eylea | 2011 | macular degeneration | VEGF inhibitor | VEGF-A and PlGF inhibitor |
Glucarpidase | Voraxaze | 2012 | methotrexate toxicity | enzyme | methotrexate inactivation |
Ingenol | Picato | 2012 | actinic keratosis. | unclear | unclear |
Axitinib | Inlyta | 2012 | renal cell carcinoma | Kinase inhibitor | tyrosine kinase inhibitor |
Vismodegib | Erivedge | 2012 | basal cell carcinoma | Hedgehog pathway inhibitor | SMO inhibitor |
Ivacaftor | Kalydeco | 2012 | cistic fibrosis | CFTR potentiator | CFTR potentiator |
Tafluprost | Zioptan | 2012 | glaucoma | prostaglandin analog | prostaglandin analog |
Lucinactant | Surfaxin | 2012 | respiratory distress syndrome | pulmonary surfactant | pulmonary surfactant |
Peginesatide | Omontys | 2012 | anemia due to chronic kidney disease | erythropoiesis-stimulating agent | erythropoietin receptor activator |
Avanafil | Stendra | 2012 | erectile dysfunction | PDE5 inhibitor | PDE5 inhibitor |
Taliglucerase alpha | Elelyso | 2012 | Gaucher disease | enzyme | Enzyme replacement therapy |
Pertuzumab | Perjeta | 2012 | breast cancer | Monoclonal antibody/HER2-blocker | HER2/neu receptor antagonist |
Lorcaserin | Belviq | 2012 | obesity | 5-HT 2C agonist | 5-HT2C receptor agonist |
Mirabegron | Myrbetriq | 2012 | Overactive bladder | Adrenergic/anticholinergic agent | β3 adrenergic agonist |
Sodium picosulfate, magnesium oxyde, citric acid | Prepopik | 2012 | colon cleansing and preparation | Bowel cleanser | peristalsis stimulator |
Carfilzomib | Kyprolis | 2012 | multiple myeloma | Proteasome inhibitor | Proteasome inhibitor |
Aclidinium | Tudorza Pressair | 2012 | COPD | Anticholinergic bronchodilator | M3 muscarinic acetylcholine antagonist |
Icosapent | Vascepa | 2012 | hypertriglyceridemia | Lipid-regulating agent | unclear |
Ziv-aflibercept | Zaltrap | 2012 | colorectal cancer | VEGF inhibitor | VEGF-A inhibitor; VEGF-B inhibitor; PIGF inhibitor |
Elvitegravir; Cobicistat; Emtricitabine; Tenofovir | Stribild | 2012 | HIV | HIV integrase strand transfer inhibitor/nucleoside analogue combination | mixture of 4 known MoAs |
Linaclotide | Linzess | 2012 | IBS; constipation | Guanylate cyclase-C agonist | Guanylate cyclase-C agonist |
Enzalutamide | Xtandi | 2012 | prostate cancer | Nonsteroidal antiandrogen | androgen receptor inhibitor |
Bosutinib | Bosulif | 2012 | leukemia | Kinase inhibitor | tyrosine kinase inhibitor |
Teriflunomide | Aubagio | 2012 | multiple sclerosis | Pyrimidine synthesis inhibitor | dihydroorotate dehydrogenase inhibitor |
Regorafenib | Stivarga | 2012 | colorectal cancer | Kinase inhibitor | tyrosine kinase inhibitor |
ocriplasmin | Jetrea | 2012 | Vitreomacular Adhesion | protease | proteolysis |
Perampanel | Fycompa | 2012 | epilepsy | AMPA receptor antagonist | AMPA receptor antagonist |
Omacetaxine | Synribo | 2012 | leukemia | protein synthesis inhibitor | protein synthesis inhibitor |
Tofacitinib | Xeljanz | 2012 | rheumatoid arthritis | Kinase inhibitor | Janus kinase inhibitor |
Cabozantinib | Cometriq | 2012 | thyroid cancer | Kinase inhibitor | tyrosine kinase inhibitor |
Ponatinib | Iclusig | 2012 | leukemia | Kinase inhibitor | tyrosine kinase inhibitor |
Raxibacumab | Raxibacumab | 2012 | anthrax | Monoclonal antibody/PA antigen-blocker | B Anthracis' Protective antigen antagonist |
Pasireotide | Signifor | 2012 | Cushing’s disease | somatostatin analog | somatostatin receptor 5 agonist |
Teduglutide | Gattex | 2012 | Short Bowel Syndrome | GLP-2 analog | GLP-2 analog |
Lomitapide | Juxtapid | 2012 | Homozygous familial hypercholesterolemia | MTP inhibitor | microsomal triglyceride transfer protein (MTP) inhibitor |
Apixaban | Eliquis | 2012 | Stroke | Specific factor Xa inhibitor | Specific factor Xa inhibitor |
Bedaquiline | Sirturo | 2012 | Tuberculosis | diarylquinoline | ATP synthase inhibitor |
Crofelemer | Fulyzaq | 2012 | Diarrhea | CFTR and CaCC inhibitor | CFTR and CaCC inhibitor |